TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer.
Over his 23-year career, Dr. Shojaei has focused on the clinical development, registration, and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.
“TearClear is disrupting the way current topical medications are delivered to the ocular surface and the uniqueness of their innovation applies to a large number of existing products within ophthalmology,” Dr. Shojaei said in a company news release. “For me, it was the novel approach to an existing problem coupled with the broad applicability of their platform that attracted me most.”
TearClear CEO, Robert Dempsey, said, “Dr. Shojaei is joining the company at a critical juncture as the organization prepares to take the lead products to clinical registration trials. He is a respected and proven leader in our industry and is joining a team of industry veterans.”
Dr. Shojaei was previously Therapeutic Area Head of Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets. Most recently, Dr. Shojaei’s team brought Xiidra from development to approval in the U.S. and in Canada, Mexico, Australia, Switzerland, South Korea, and the Gulf countries.